相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies
Varun V. Prabhu et al.
CELL CYCLE (2018)
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
Isabel Arrillaga-Romany et al.
ONCOTARGET (2017)
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Mark N. Stein et al.
CLINICAL CANCER RESEARCH (2017)
Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Prithviraj Bose et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Evolution of acute myelogenous leukemia stem cell properties after treatment and progression
Tzu-Chieh Ho et al.
BLOOD (2016)
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
Jo Ishizawa et al.
SCIENCE SIGNALING (2016)
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
Jo Ishizawa et al.
SCIENCE SIGNALING (2016)
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
Joshua E. Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
分享论文
